Benzinga | Apr 20, 2021 07:20AM EDT

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia

- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-

- Revised agreement provides Vertex with 60% and CRISPR with 40% of- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-



- Revised agreement provides Vertex with 60% and CRISPR with 40% of program economics-

- CRISPR to receive $900 million upfront payment with potential for additional $200 million milestone payment upon CTX001 regulatory approval -